In Graves disease, the clinical uses of thyrotropin receptor [thyroidstimulating hormone receptor (TSH-R) 1 ] antibody (TRAb) measurements have been reported in the Thyroid Guidelines of the American Thyroid Association (1 ) . First, TRAb measurements are used to investigate the etiology of hyperthyroidism when the diagnosis is not clinically obvious; second, a declining TRAb concentration during long-term antithyroid drug therapy is suggestive of remission, although TRAb measurements can be misleading in 25% of such patients; third, TRAb is used in the follow-up of pregnant women with a history or recent onset of Graves disease to evaluate the risk of fetal and neonatal thyroid dysfunction (1 ) . In the late 1990s, the secondgeneration TRAb assays that use recombinant human TSH-R replaced the first-generation methods, which were too insensitive in the diagnosis of Graves disease (1 ). However, third-generation TRAb assays, which use the monoclonal thyroid-stimulating antibody M22 labeled either with biotin in ELISAs or with ruthenium in the automated Elecsys®/Cobas®, have also been developed. It is now established that these third-generation assays have no clinical advantages over second-generation methods in the diagnosis (2, 3 ) or in the follow-up of Graves disease patients (4 ). Recently, it has been reported that the automated third-generation TRAb assays should be performed on clinical chemistry platforms and should prompt appropriate revision of the current thyroid guidelines (2 ) . The scientific community should be aware of the consequences of such a decision. We demonstrated that the second-generation and the third-generation TRAb assays exhibited a high intermethod variability, despite the use of the same reference standard for calibration to National Institute for Biological Standards and Control (NIBSC) 90/672 (3, 4 ) . This variability may lead to misinterpretation of results (5 ) 
